**Updated June 2013**

**MarketVIEW: Yellow Fever vaccines (CAT: VAMV019)**

| **Product Name** : | MarketVIEW: yellow fever vaccines |
| **Description** : | Global vaccine commercial opportunity assessment |
| **Contents** : | Executive presentation + 2 forecast models |
| **Therapeutic Area** : | Travel/endemic vaccines |
| **Publication date** : | June 2013 |
| **Catalogue No** : | VAMV019 |

**Background**

Yellow Fever (YF) is a mosquito-borne disease caused by the Amaril virus which has symptoms that range from mild to severe illness and even death (est 30,000/yr). The disease, which exists in various forms, is mainly endemic to parts of Africa and Latin America (LATAM) where 610 million are estimated to be at risk of which 219 million are living in urban settings.

Yellow fever vaccination, using a one shot live-attenuated vaccine based on 17-D is the most important measure to control YF and has been available for decades. It is currently used in routine childhood immunization (6-9 mos) and as part of donor funded mass vaccination campaigns operated by the YF initiative (WHO/UNICEF). YF vaccine is also used by Western travelers (YF-VAX, Stamaril, Sanofi Pasteur) to endemic regions where certification is required for entry. Various militaries also use YF vaccine for troops stationed in certain areas.

This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Yellow Fever vaccination across endemic, travelers and military markets to 2030. The model contains value ($m) and volume (mio doses) predictions/with supplier volume analysis. Safety considerations of current vaccines are discussed along with new inactivated vaccines e.g. Xcellerex Inc which also have been forecasted at varying pricing levels.
Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Yellow Fever epidemiology/vaccines and. Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by VacZine Analytics in field of travel and endemic vaccines has also been utilised.

PRODUCT CONTENTS:
Updated June 2013 (CAT No: VAMV019)

****This product is composed of a model and summary presentation

Contents – Summary presentation (MS PowerPoint based)
Author's note
Executive Summary
Yellow Fever vaccines: total value ($m) – premium price
Yellow Fever vaccines: total value ($m) – parity price
Yellow Fever vaccines: total volume (000s doses)
Yellow Fever vaccines: volume by market segment (000s)
Yellow Fever vaccines: value by market segment ($m) – premium price
Yellow Fever vaccines: travel market value by vaccine ($m) – premium price
Yellow Fever vaccines: military market value by vaccine ($m) – premium price
Yellow Fever vaccines: value by market segment ($m) – parity price
Yellow Fever vaccines: travel market value by vaccine ($m) – parity price
Yellow Fever vaccines: military market value by vaccine ($m) – parity price
Population segments modelled
Routine infant immunization: model assumptions
Mass preventive campaigns: model assumptions
Travel market (Western): model assumptions
Military market (US): model assumptions
Novel Yellow Fever vaccines: model assumptions
Novel Yellow Fever vaccines: pricing assumptions
Yellow Fever vaccine opportunity: target product profile
Yellow Fever risk areas
Yellow Fever vaccines
SAGE updated vaccine recommendations
Yellow Fever live vaccines: adverse events
Routine childhood immunization: national policies
Preventive vaccine campaigns
Travel market: North America/Europe
Military market (US): model assumptions
Novel Yellow Fever vaccines: model assumptions
Yellow Fever vaccine opportunity: target product profile
Yellow Fever risk areas
Yellow Fever vaccines
SAGE updated vaccine recommendations
Yellow Fever live vaccines: adverse events
Continued..........

Routine childhood immunization: national policies
Preventive vaccine campaigns
Travel market: North America/Europe
Military market (US)
Yellow Fever vaccines: global supply
Novel Yellow Fever vaccines
Bibliography
About VacZine Analytics
Disclaimer

PAGES: 62 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model(s) (MS Excel-based) – 2 models

Title sheet
Scenario definitions
Charts value
Charts volume
All value (live and inact)
All volume (live and inact)
Travel value (live and inact)
Travel volume (live and inact)
Mass campaigns value (live)
Mass campaigns of volume (live)
Infant value (live)
Infant (liv volume)
Nigeria (infant)
DRC (infant)
Ghana (infant)
Niger (infant)
Burkina Faso (infant)
Mali (infant)
Cote D’Ivore (infant)
Angola (infant)
Angola (infant)
Cameroon (infant)
Senegal (infant)
Kenya (infant)
Africa other (infant)
Africa infant (new)
Uganda (infant)
South Sudan (infant)
Equatorial Guinea (infant)
LATAM infant (existing)
Brazil
Other LATAM
Mass campaigns
Nigeria
South Sudan.
DRC
Congo
Gabon
Chad
Continued.........

Uganda.
Brazil
Travel and Military =>
US and Canada
Europe
US military
Source material =>
Births
Total population
Model inputs
Price summary
Campaigns-Africa
YFV coverage (WHO)
YFV coverage (official)
YF incidents
Brazil NIP
Trips (base data)
Trips (grouped)
Travel market variables
Back-page

WORKSHEETS: ~65
PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- **USD $8995.00/ GBP £5995.00** (Region license)*

*A region is North America, Europe or ROW
For orders in the UK, VAT at 20.0% will be added to final invoice total

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com
This report can also be purchased on-line. Please review the TERMS and CONDITIONS of purchase.

---

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and the “spiral logo” are UK Registered Trademarks, 2009
BIBLIOGRAPHY:


4. WHO. Yellow fever in Africa and South America, 2006. Weekly Epidemiological Record. 2008;83(8):60-76


TERMS and CONDITIONS:
VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client’s acceptance of the Service according the description proposed by the Company.
3. Cancellation policy. The Company’s cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. Cancellation rights: For finished documents - a Clients cancellation rights will last for seven working days counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will 100% after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within thirty days of the invoice date.
7. All proposals are quoted in $USD dollars or £GBP and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company’s employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master TERMS and CONDITIONS available upon request.

VacZine Analytics
Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com
About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728
VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009